{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:17:29Z","timestamp":1790713049113,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:00:00Z","timestamp":1679443200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002619","name":"Ajou University","doi-asserted-by":"publisher","award":["1\/2"],"award-info":[{"award-number":["1\/2"]}],"id":[{"id":"10.13039\/501100002619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002619","name":"Ajou University","doi-asserted-by":"publisher","award":["DF6002"],"award-info":[{"award-number":["DF6002"]}],"id":[{"id":"10.13039\/501100002619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002619","name":"Ajou University","doi-asserted-by":"publisher","award":["WO 2020\/086758"],"award-info":[{"award-number":["WO 2020\/086758"]}],"id":[{"id":"10.13039\/501100002619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.medj.2023.03.007","type":"journal-article","created":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T14:14:28Z","timestamp":1681395268000},"page":"326-340.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["An optimized IL-12-Fc expands its therapeutic window, achieving strong activity against mouse tumors at tolerable drug doses"],"prefix":"10.1016","volume":"4","author":[{"given":"Eva","family":"Gutierrez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Bigelow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"LaCroix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Beech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Kirby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Markowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Shifrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Naill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"O\u2019Neil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marie","family":"Cuillerot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asya","family":"Grinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolai","family":"Wagtmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2023.03.007_bib1","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.immuni.2019.03.011","article-title":"The immunobiology of the interleukin-12 family: room for discovery","volume":"50","author":"Tait Wojno","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.medj.2023.03.007_bib2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1006\/cimm.1999.1589","article-title":"Identification of IFN-gamma-producing cells in IL-12\/IL-18-treated mice","volume":"198","author":"Otani","year":"1999","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.medj.2023.03.007_bib3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/00002371-199308000-00012","article-title":"Interleukin-12 promotes the proliferation and cytolytic maturation of immune effectors: implications for the immunotherapy of cancer","volume":"14","author":"Zeh","year":"1993","journal-title":"J.\u00a0Immunother. Emphasis Tumor Immunol."},{"key":"10.1016\/j.medj.2023.03.007_bib4","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/0955-2235(92)90016-B","article-title":"Natural killer cell stimulatory factor (NKSF) or interleukin-12 is a key regulator of immune response and inflammation","volume":"4","author":"Trinchieri","year":"1992","journal-title":"Prog. Growth Factor Res."},{"key":"10.1016\/j.medj.2023.03.007_bib5","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1172\/JCI0215950","article-title":"IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells","volume":"110","author":"Parihar","year":"2002","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.medj.2023.03.007_bib6","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.immuni.2018.09.024","article-title":"Successful anti-PD-1 cancer immunotherapy requires T\u00a0cell-dendritic cell crosstalk involving the cytokines IFN-\u03b3 and IL-12","volume":"49","author":"Garris","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.medj.2023.03.007_bib7","first-page":"1183","article-title":"Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma","volume":"4","author":"Motzer","year":"1998","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2023.03.007_bib8","first-page":"409","article-title":"Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies","volume":"3","author":"Atkins","year":"1997","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2023.03.007_bib9","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1084\/jem.178.4.1223","article-title":"Antitumor and antimetastatic activity of interleukin 12 against murine tumors","volume":"178","author":"Brunda","year":"1993","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.medj.2023.03.007_bib10","first-page":"2541","article-title":"Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production","volume":"90","author":"Leonard","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.medj.2023.03.007_bib11","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1479-5876-5-66","article-title":"Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease\u00a0<\u00a01\u00a0cm) associated with ovarian cancer or primary peritoneal carcinoma","volume":"5","author":"Lenzi","year":"2007","journal-title":"J.\u00a0Transl. Med."},{"key":"10.1016\/j.medj.2023.03.007_bib12","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw2614","article-title":"Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy","volume":"11","author":"Momin","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.medj.2023.03.007_bib13","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abn5859","article-title":"Intratumoral immunotherapy relies on B and T\u00a0cell collaboration","volume":"7","author":"Sagiv-Barfi","year":"2022","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.medj.2023.03.007_bib14","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1158\/1078-0432.CCR-18-1512","article-title":"First-in-Human phase I trial of a tumor-targeted cytokine (NHS-IL12) in subjects with metastatic solid tumors","volume":"25","author":"Strauss","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2023.03.007_bib15","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1158\/1078-0432.CCR-19-2217","article-title":"Phase II trial of IL-12 plasmid transfection and PD-1 blockade in immunologically quiescent melanoma","volume":"26","author":"Algazi","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2023.03.007_bib16","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw5680","article-title":"Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: results of a phase 1 trial","volume":"11","author":"Chiocca","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.medj.2023.03.007_bib17","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abi6899","article-title":"A tumor-specific pro-IL-12 activates preexisting cytotoxic T\u00a0cells to control established tumors","volume":"7","author":"Xue","year":"2022","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.medj.2023.03.007_bib18","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1158\/1078-0432.CCR-10-2490","article-title":"A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma","volume":"17","author":"Rudman","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2023.03.007_bib19","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1438800","article-title":"Heterodimeric Fc-fused IL12 shows potent antitumor activity by generating memory CD8+ T\u00a0cells","volume":"7","author":"Jung","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.medj.2023.03.007_bib20","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.4049\/jimmunol.148.11.3433","article-title":"Cloning and expression of murine IL-12","volume":"148","author":"Schoenhaut","year":"1992","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.medj.2023.03.007_bib21","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3389\/fimmu.2016.00394","article-title":"Immunoglobulin Fc heterodimer platform technology: from design to applications in therapeutic antibodies and proteins","volume":"7","author":"Ha","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.medj.2023.03.007_bib22","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1074\/jbc.M116.767749","article-title":"Effector-attenuating substitutions that maintain antibody stability and reduce toxicity in mice","volume":"292","author":"Lo","year":"2017","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.medj.2023.03.007_bib23","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s13238-017-0473-8","article-title":"IgG Fc engineering to modulate antibody effector functions","volume":"9","author":"Wang","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.medj.2023.03.007_bib24","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/s41577-018-0029-z","article-title":"IFN\u03b3: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy","volume":"18","author":"Ivashkiv","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.medj.2023.03.007_bib25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00281-018-0714-9","article-title":"Developing combination strategies using PD-1 checkpoint inhibitors to treat cancer","volume":"41","author":"Schmidt","year":"2019","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.medj.2023.03.007_bib26","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1158\/2326-6066.CIR-16-0114","article-title":"Rational selection of syngeneic preclinical tumor models for immunotherapeutic drug discovery","volume":"5","author":"Mosely","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.medj.2023.03.007_bib27","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1177\/019262339902700112","article-title":"The toxicology of interleukin-12: a review","volume":"27","author":"Car","year":"1999","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.medj.2023.03.007_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2019.05.002","article-title":"IFN-\u0393: a cytokine at the right time, is in the right place","volume":"43","author":"Burke","year":"2019","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.medj.2023.03.007_bib29","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S1074-7613(00)80378-7","article-title":"IGIF does not drive Th1 development but synergizes with IL-12 for interferon-gamma production and activates IRAK and NFkappaB","volume":"7","author":"Robinson","year":"1997","journal-title":"Immunity"},{"key":"10.1016\/j.medj.2023.03.007_bib30","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1600-065X.1999.tb01329.x","article-title":"Regulation of the IL-12\/IL-12R axis: a critical step in T-helper cell differentiation and effector function","volume":"170","author":"Sinigaglia","year":"1999","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.medj.2023.03.007_bib31","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.4049\/jimmunol.164.6.3330","article-title":"IFN-gamma-dependent and -independent mechanisms in adverse effects caused by concomitant administration of IL-18 and IL-12","volume":"164","author":"Nakamura","year":"2000","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.medj.2023.03.007_bib32","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.4049\/jimmunol.168.5.2282","article-title":"IL-12 induces monocyte IL-18 binding protein expression via IFN-gamma","volume":"168","author":"Veenstra","year":"2002","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.medj.2023.03.007_bib33","first-page":"1678","article-title":"Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response","volume":"6","author":"Gollob","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2023.03.007_bib34","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","article-title":"Tumor-residing Batf3 dendritic cells are required for effector T\u00a0cell trafficking and adoptive T\u00a0cell therapy","volume":"31","author":"Spranger","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.medj.2023.03.007_bib35","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3389\/fcell.2020.00351","article-title":"Friend or foe? Recent strategies to target myeloid cells in cancer","volume":"8","author":"Chaib","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.medj.2023.03.007_bib36","doi-asserted-by":"crossref","DOI":"10.1177\/11795549211035540","article-title":"Targeting MDSC for immune-checkpoint blockade in cancer immunotherapy: current progress and new prospects","volume":"15","author":"Li","year":"2021","journal-title":"Clin. Med. Insights Oncol."},{"key":"10.1016\/j.medj.2023.03.007_bib37","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1078-0432.CCR-16-0224","article-title":"Dual faces of IFN\u03b3 in cancer progression: a role of PD-L1 induction in the determination of pro- and antitumor immunity","volume":"22","author":"Mandai","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2023.03.007_bib38","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1126\/science.aaf2834","article-title":"Cancer immunology. The \u201ccancer immunogram\u201d","volume":"352","author":"Blank","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.medj.2023.03.007_bib39","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","article-title":"Hallmarks of response, resistance, and toxicity to immune checkpoint blockade","volume":"184","author":"Morad","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.medj.2023.03.007_bib40","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.medj.2023.03.007_bib41","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T\u00a0cell dysfunction and exclusion predict cancer immunotherapy response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat. Med."}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634023001034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634023001034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T02:56:45Z","timestamp":1763002605000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634023001034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S2666634023001034"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2023.03.007","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An optimized IL-12-Fc expands its therapeutic window, achieving strong activity against mouse tumors at tolerable drug doses","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2023.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}